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Abstract Muscarinic toxin 3 (MT3) (65 amino acids, four disulphides, M, 7379) was isolated from the venom of the African snake Dendroaspis 
angusticeps (green mamba) and its amino acid sequence determined. Its ability to inhibit the binding of [3H]N-methylscopolamine ([fH]NMS) to 
Chinese hamster ovary cells stably expressing subtypes of muscarinic receptors was studied. MT3 displayed high affinity for the m4 receptor 
(pK, = 8.7 It 0.06), 40-fold lower affinity at ml receptors (pK, = 7.11 + 0.17) whereas no inhibition of [3H]NMS binding to m2, m3 and m5 receptors 
was observed at concentrations up to 1 PM. This makes MT3 the most selective m4 receptor ligand known to date. 
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1. Introduction 
Muscarinic acetylcholine receptors are coupled to G-pro- 
teins, which in turn activate different second messengers and 
ion channels [ 1,2]. There are currently five subtypes of muscar- 
inic receptors which are differentially distributed in tissues. For 
instance, the heart contains primarily m2 receptors whereas all 
five subtypes are found in the brain. The function of these 
different muscarinic receptors in the central nervous system 
remains unclear due, in part, to the lack of highly selective 
agonists and antagonists. 
Natural toxins that are selective for subtypes of nicotinic 
acetylcholine receptors are known; a-neurotoxins from snakes 
[3,4] and a-conotoxins from predatory snails, genus Conus 
[46], are specific probes for receptors in skeletal muscles, and 
K-bungarotoxin [3,4] and the newly discovered a-conotoxin ImI 
[7] are probes for neuronal nicotinic receptors. 
Nature also provides toxins that discriminate among sub- 
types of muscarinic receptors. Mambas, African snakes of 
genus Dendroaspis, have such toxins. Already the first report 
on these so-called muscarinic toxins [8] indicated that they 
might have some selectivity as evidenced by the fact that these 
toxins inhibited only 50% of the binding of the nonselective 
radioligand [3H]quinuclidinyl benzilate to synaptosomal mem- 
branes prepared from rat cerebral cortex. Later, a toxin called 
ml-toxin was isolated from the venom of the green mamba, 
Dendroaspis angusticeps, and shown to be highly selective for 
ml receptors [9]. 
Here we report the isolation, characterization and amino 
acid sequence of a new toxin from green mamba venom, mus- 
carinic toxin 3 (MT3), that is highly selective for m4 receptors, 
a subtype for which no specific ligand is currently available. 
2. Materials and methods 
2. I. Materials 
Lyophilized Dendroaspis angusticeps venom was purchased from 
*Corresponding author. Fax: (46) (18) 552 139. 
Jonathan Leaky Ltd, P.O. Box 1141, Nakuru, Kenya. Atropine and 
pirenzepine were from Sigma, Saint Quentin Fallavier, France, him- 
bacine was a generous gift of Dr. W.C. Taylor, University of Sydney, 
Sydney, Australia and [‘H]NMS from Amersham, Les Ulis, France. 
2.2. Isolation and characterization of the toxin 
Isolation was carried out essentially as described earlier [5] by gel 
filtration on Sephadex G-50, chromatography on the cation-exchangers 
Bio-Rex 70 (polymer of methacrylic acid cross-linked with divinylben- 
zene) and SP-Sephadex C-25 (SP = sulphopropyl). Finally, the toxin 
was submitted to ion-exchange HPLC on a BioGel TSK SP-5-PW 
column (21.5 x 150 mm). The purity was checked by reversed-phase 
HPLC on a C4 and Cl 8 column using a gradient of acetonitrile in 0.1% 
trifluoroacetic acid. 
Amino acid analysis, plasma desorption mass spectrometry, hy- 
drazinolysis, preparation of a pyridyl ethyl cysteine (PEC) derivative 
and Edman degradation were carried out as reported earlier [11,12]. 
For cleavage at tryptophan, the PEC derivative was dissolved in 75% 
acetic acid containing BNPS-skatole (50 times molar excess to trypto- 
phan) 0.1% phenol as scavenger to protect tyrosine residues against 
modification [12]. The mixture was incubated in darkness at 20°C for 
32 hours. The fragments were separated by gel filtration on a TSK 
HW-40 column (1.4 x 102 cm) in 50% acetic acid. The peak containing 
the terminal fragment 29-65 was identified by its spectrum (PEC and 
Tyr absorbance, maximun at 255 and 276 nm, respectively). It was 
purified further by cation exchange HPLC on BioGel TSK SP-5-PW 
in ammonium acetate, pH 6.7, and submitted to amino acid analysis 
and Edman degradation. 
2.3. Receptors 
Chinese hamster ovary (CHO) cells stably expressing one of the five 
muscarinic receptor subtypes were cultured using standard techniques. 
Upon confluency, cells were scraped and homogenized with a polytron, 
setting 6 for 15 set in 10 ml 50 mM sodium potassium phosphate buffer, 
pH 7.4 (used throughout in the following steps). The homogenate was 
centrifuged at 40,000 x g for IO min at 4°C. The pellet was resuspended 
to obtain 50-400 mg/ml depending on the receptor subtype. The con- 
centration of MT3 was determined spectrophotometrically and 1 I dilu- 
tions were made for each experiment. Incubation tubes contained 
200 ~1 buffer, 50 ~1 [3H]NMS (final concentration 0.3 nM), 50~1 toxin, 
pirenzepine or himbacine and 200 ~1 homogenate. Nonspecific binding 
was determined as the binding in the presence of 2 PM atropine. After 
a 1 h (CHO-ml-m4) or I .5 h (CHO-m5) incubation at room tempera- 
ture (19-21°C) bound and free radioligand were separated by rapid 
filtration through glass fibre filters using a 96-well cell harvester. Filter- 
bound radioactivity was quantified by solid scintillation spectrometry. 
Competition curves were analyzed by fitting the data to a four- 
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parameter logistic equatior rg the curve-fitting program InPlot (ver- 
sion 4, GraphPad Software, San Diego, CA). K, values were calculated 
using the ChenggPrusoff equation K, = IC,J(l+[L]IK,) [13], where 
[L](KJ; concentration (dissociation constant) of [‘HINMS. Kd values 
were determined from saturation experiments performed under the 
same conditions as described above. 
3. Results 
3.1. Isolation of toxin MT3 
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The two first isolation steps using gel filtration on Sephadex 
G-50 and chromatography on the cation-exchanger Bio-Rex 70 
are described in detail elsewhere [6]. In chromatography on 
SP-Sephadex C-25, more shallow gradients were used than 
before which considerably improved the resolution. With the 
ion-exhanger, equilibrated at pH 5.2, two peaks (Fig. 1A) were 
obtained that displaced [3H]NMS from its binding sites on 
synaptosomal membranes from porcine brain. The peaks were 
pooled, pH adjusted to 7 with ammonia, freeze-dried and sub- 
mitted to chromatography on SP-Sephadex C-25 at pH 6.7. 
Peak I (Fig. 1A) contained four toxins (Fig. 1B) and peak II 
three (Fig. IC). Only two of the toxins, MT1 and -2, were 
known earlier [8]. The toxins were called in the order in which 
they were detected. Because of its subtype specificity muscar- 
inic toxin 3 (MT3) was characterized further. Data on the other 
new toxins will be reported later. 
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After HPLC ion-exchange on BioGel SP-5-PW (buffer A: 
H,O, buffer B: 1.00 M ammonium acetate, pH 6.7) the toxin 
was homogeneous in analytical reversed phase HPLC on both 
a C4 and C I8 column. 
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3.2. Amino acid composition and sequence 
A molar ratio of 8.5 for Thr was repeatedly obtained in the 
analysis of MT3 (Table 1). Mass spectrometry gave a molecular 
Table I 
Amino acid composition of MT3 
Amino acid Acid hydrolysis Sequence 
Molar ratio (Integer)* 
ASP 7.12 f 0.12 (7) 2 
Asn 5 
Thr 8.47 + 0.07 (9) 9 
Ser 1.26 f 0.01 (1) I 
Glu 5.18 f 0.05 (5) 4 
Gln I 
Pro 3.98 f 0. I I (4) 4 
GlY 3.08 f 0.02 (3) 3 
Ala 2.93 f 0.08 (3) 3 
Half-cys 7.98 f 0.21 (8) 8 
Val 2.16 f 0.05 (2) 2 
Met 0.00 (0) 0 
Be 5.65 + 0.00 (6) 6 
Leu 2.14 f 0.00 (2) 2 
Tyr 3.00 f 0.02 (3) 3 
Phe 2.00 f 0.01 (2) 2 
His I .94 + 0.04 (2) 2 
LYS 4.10 f 0.01 (4) 4 
Arg 3.00 f 0.03 (3) 3 
Trp (1) I 
No. of residues 65 65 
Molecular weight 7379 
Molar absorptivity at 276 nm 11,100 
A0 1% 1.50 
*Average of two analyses. Hydrolysis; 6 M HCI, 24 h, 110°C. 
9 Thr concluded from mass spectrometry. Absorption maximum at 
276 nm. 
Fig. I. Ion-exchange chromatography on SP-Sephadex C-25 (2.0 x 28 
cm) equilibrated with buffer A. Freeze-dried sample dissolved in buffer 
A applied to column. Elution with buffer A until all non- adsorbed 
material had come out and then with a concave gradient of 900 ml 
buffer A vs. 400 ml buffer B. Gradient formed by two connected 
cylinders of diameters 9 cm (buffer A) and 6 cm (buffer B). Flow rate 
25 ml/h. Fraction collection started at beginning of gradient elution. 
A,,, (absorbance at 280 nm), arbitrary scale. (A) Sample from totally 
9 g venom: non-retarded fraction from run on Bio-Rex 70 [8]. Buffer 
A: 0.05 M AmOAc (pH 5.2), buffer B: I .OO M AmOAc (pH 6.5). I3 ml 
fractions. Activity, inhibition of [‘HJNMS binding to synaptosomal 
membranes, in peaks I and II. (B) Sample peak I (IA). Buffer A: IO mM 
AmOAc (pH 6.7), B: I,00 M AmOAc (pH 6.7). Buffers by dilution of 
5 M stock solution without pH adjustment. I2 ml fractions. MT = 
muscarinic toxin. (C) Sample peak II (IA). Buffers as in B. 9 ml frac- 
tions. 
weight of 7360, a value in better agreement with the molecular 
weight from amino acid analysis (7385) assuming 9 Thr rather 
than 8 Thr (7284). Sequence determination confirmed that the 
toxin has 9 Thr residues and 65 amino acids. 
The molar absorptivity at pH 7 and 276 nm (absorbance 
maximum) was 11,100 M-’ .cm-‘. The toxin has one trypto- 
phan, since the sum of the molar absorptivities of 3 Tyr (4101), 
4 cystine (440) and 1 Trp (5431) = 9972. The difference I28 
(10%) is the contribution from secondary and tertiary struc- 
tures. 
Two nanomoles PEC derivative was sequenced to amino acid 
43 without any impurities being detected. The yield of the first 
phenylthiohydantoin amino acid was 50% and the repetitive 
yield, i.e. the yield in one step compared to that of the preceding 
step, averaged 94%. The fragment from cleavage at Trp was 
sequenced from amino acid 29 to 65, glutamic acid. The 
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Fig. 2. Primary structures of MT3 (selective for muscarinic receptors 
of subtype m4) and ml-toxin (selective for ml) [9]. Invariant amino 
acids are indicated by two dots. 
C-terminal amino acid was Glu, since hydrazinolysis of the 
native toxin gave Glu in a yield of 94% and no traces of other 
amino acids. 
The following sequence was obtained: 
It agrees with data from amino acid analysis, mass spectrom- 
etry and hydrazinolysis. 
3.3. Binding to subtypes of muscarinic receptors 
In saturation experiments, it was shown that the radioligand, 
[3H]NMS, displayed dissociation constants, Kd, of 96, 140, 74, 
72 and 240 pM for ml, m2, m3, m4 and m5 receptors, respec- 
tively. 
MT3 displayed high affinity (pK, = 8.7) for the m4 receptor 
which was 40 times higher than for the ml receptor (pK, = 7.11) 
and no binding of the toxin to m2, m3 and m5 receptors 
(pK, < 6) could be detected (Table 2). The Hill coefficients are 
close to 1, indicating binding to one site. For comparison, the 
affinity values are reported for two compounds,pirenzepine 
and himbacine, that have been used as pharmacological tools 
to distinguish ml and m4 receptors (Table 2). It is evident that 
93 
MT3 is considerably more selective for one receptor than piren- 
zepine and himbacine. 
4. Discussion 
Ammonium acetate buffers were used in the isolation be- 
cause the samples can be freeze-dried directly without prior 
desalting. Buffers with high capacity are usually recommended 
for ion-exchange [14], but buffers with very low capacity can, 
evidently, also give good resolution (Fig. 1B and C). Buffering 
capacity of ammonium acetate is minimal at neutral pH. The 
nature of the buffer ions can also be important, for instance, 
acetate often gives a better resolution than chloride [15]. 
Several remarkable neurotoxins have been isolated from the 
venom of the green mamba: dendrotoxins, blockers of voltage- 
dependent potassium channels [ 161; fasciculins, non-competi- 
tive inhibitors of acetylcholinesterase [ 171 and muscarinic tox- 
ins. An important aspect of these toxins is their selectivity for 
various subtypes of the target molecules. Dendrotoxins can 
distinguish between different types of voltage-dependent potas- 
sium channels [ 181, fasciculins inhibit mammalian but not insect 
acetylcholinesterases [17]. Some of the muscarinic toxins iso- 
lated from green mamba venom are also selective; MT3 for m4 
receptors (this report) and ml-toxin for ml receptors [9]. 
A comparison of the sequences of the two toxins (Fig. 2) 
shows a high homology; they have the same amino acidin 40 
of the 65 positions. The amino acids that determine the subtype 
specificity should be in the parts of the molecules that are 
different. The central part, residues 21-38, contains 6 or 7 
hydrophobic amino acids (F, I. L, V, W, Y) which is character- 
istic of muscarinic toxins [l 11. 
Currently, no ligands selective for m4 receptors are available. 
In binding studies using human recombinant muscarinic recep- 
tors, the affinity of pirenzepine, a compound used as an ml 
receptor selective ligand, for m4 receptors was only 5-fold lower 
than its affinity for ml receptors (Table 2) [19]. The alkaloid 
himbacine isolated from the bark of Australian trees of Galbu- 
limima species (Ritchie and Taylor, 1967, cited in [20]) dis- 
played the same (Table 2) [ 191 or slightly lower (about half [21]) 
affinity for m4 than for m2 receptors. The new toxin MT3 is 
highly selective (> 500-fold) for m4 receptors compared to n-12 
and has a sufficiently high selectivity for m4 compared to ml 
(40-fold) and m3 and m5 (> 500-fold) that it should be a useful 
tool for investigating the distribution and function of m4 recep- 
tors in various organs and tissues. Specifically, it should be 
useful to characterize autoreceptors in brain which have been 
proposed to be of the subtype m2 [22], m3 [24] or m4 [23]. 
Acknowledgements: This work was supported by the Swedish Natural 
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Table 2 
Affinity constants (p&) and Hill constants (nH) of MT3, pirenzepine and himbacine for subtypes of muscarinic receptors. Values are expressed as
mean If: S.D., n = 4 (MT3) or 34 (pirenzepine, himbacine) 
Compound MT3 Pirenzepine Himbacine 
PK, nH PK, nH PK, nH 
ml 7.11 f 0.11 0.94 f 0.01 7.97 f 0.09 0.88 f 0.03 6.68 f 0.05 0.95 f 0.04 
m2 ~6 6.33 t 0.07 0.89 f 0.02 7.92 f 0.15 0.94 f 0.05 
m3 ~6 6.65 f 0.09 1.07 f 0.16 6.85 f 0.05 0.99 + 0.1 I 
m4 8.70 f 0.06 1.00 f 0.11 7.30 f 0.17 0.91 f 0.04 7.88 f 0.07 1.38 + 0.26 
m5 ~6 6.88 f 0.04 0.95 f 0.08 5.35 f 0.38 0.88 ?r 0.03 
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